Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05855369 · ClinicalTrials.gov registry record · Phase 2

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

A Phase 2 study of Long COVID and Olfactory Disorder, sponsored by Medical University of South Carolina.

Recruiting
Registry status
Phase 2
Development phase
180
Enrollment target
1
Study location

NCT05855369: Recruiting Phase 2 study of Long COVID and Olfactory Disorder, sponsored by Medical University of South Carolina.

NCT05855369 is a Phase 2 study of Long COVID and Olfactory Disorder that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 180 participants, below the 2,185-participant average among 50 other Long COVID trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05855369, a Phase 2 study of Long COVID and Olfactory Disorder, is actively recruiting participants, sponsored by Medical University of South Carolina.

RECRUITING
Registry status
Phase 2
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss. This study aims to determine the efficacy of two at-home treatments, smell training and non-invasive trigeminal nerve stimulation. This study requires participants to conduct daily at-home treatment sessions, attend three in-person study visits at the MUSC Department of Psychiatry and Behavioral Sciences, and complete electronic questionnaires over the 12-week trial, and again at the six-month timepoint. Participants in this trial may benefit directly with an improvement in sense of smell. However, participation may also help society more generally, as this study will provide new information about long COVID-related smell loss and its treatment.

Primary Outcome

Sniffin' Sticks (Bughardt Messtechnik, Wedel Germany) will be used to determine odor threshold (T), odor discrimination (D), and odor identification (I), each on 16-point scales, and summed for a total TDI score. Higher scores indicate better function.

Conditions Studied

Long COVID Olfactory Disorder Smell Dysfunction

Interventions

  • DEVICE Trigeminal Nerve Stimulation (TNS)
  • OTHER Active Smell Training (ST)
  • OTHER Placebo Smell Training (PBO)

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2023-10-02
Est. Completion 2028-05-31
Phase Phase 2
Medical University of South Carolina

755 total trials

What NCT05855369 shows while recruiting

NCT05855369 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 2,185-participant average among 50 other Long COVID trials with a reported enrollment target (92% lower).

The record links to 3 conditions, with Long COVID appearing as the primary indexed condition, and to 3 interventions - of which Trigeminal Nerve Stimulation (TNS) is the first listed.

NCT05855369 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT05855369 about?

NCT05855369 is a clinical study titled "Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)". Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss. This study aims to determine the efficacy of two at-home treatments, smell training and non-invasive trigem...

What is the current status of trial NCT05855369?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2023-10-02. Estimated completion is 2028-05-31.

What conditions does trial NCT05855369 study?

This clinical trial studies the following conditions: Long COVID, Olfactory Disorder, Smell Dysfunction.

What interventions are being tested in trial NCT05855369?

The interventions under investigation include: Trigeminal Nerve Stimulation (TNS) (DEVICE), Active Smell Training (ST) (OTHER), Placebo Smell Training (PBO) (OTHER).

Who is sponsoring clinical trial NCT05855369?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05855369 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Long COVID

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05855369's enrollment target sits among peer trials

180 19th of 50 higher than 31 of 50 other Long COVID trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05855369

Source: ClinicalTrials.gov NCT05855369, the US trial registry maintained by the National Library of Medicine. NCT05855369 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.